ACADIA Pharmaceuticals Inc. Stock

$20.98

4.90% day before yesterday

Nasdaq, Jul 11, 10:01 pm CET

ISIN

US0042251084

Symbol

ACAD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

ACADIA Pharmaceuticals Inc. Stock price

$20.98

-31.34 59.90% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-1.08 4.90%

ISIN

US0042251084

Symbol

ACAD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$3.5b

Enterprise Value

$2.8b

Net debt

positive

Cash

$682.0m

Shares outstanding

167.0m

Valuation (TTM | estimate)

P/E

15.3 | 39.2

P/S

3.5 | 3.2

EV/Sales

2.8 | 2.6

EV/FCF

57.2

P/B

4.6

Financial Health

Equity Ratio

61.7%

Return on Equity

30.8%

ROCE

28.4%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$996.0m | $1.1b

EBITDA

$235.9m | $87.5m

EBIT

$235.0m | $89.3m

Net Income

$229.0m | $89.3m

Free Cash Flow

$49.5m

Growth (TTM | estimate)

Revenue

22.4% | 13.3%

EBITDA

3,974.4% | -12.4%

EBIT

4,939.4% | 6.3%

Net Income

17,715.4% | -60.5%

Free Cash Flow

-22.2%

EPS

$1.4

FCF per Share

$0.3

Short interest

14.5%

Employees

654

Rev per Employee

$1.5m

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

??

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

18x Buy

69%

7x Hold

27%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy

69%

Hold

27%

Sell

Analyst Estimates with Stock Price Targets

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	996 996	22% 22% 100%
- Direct Costs	79 79	25% 25% 8%
Gross Profit	917 917	22% 22% 92%
- Selling and Administrative Expenses	506 506	22% 22% 51%
- Research and Development Expense	- -	- -
EBITDA	236 236	3,974% 3,974% 24%
- Depreciation and Amortization	0.91 0.91	91% 91% 0%
EBIT (Operating Income) EBIT	235 235	4,939% 4,939% 24%
Net Profit	229 229	17,715% 17,715% 23%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ACADIA Pharmaceuticals Inc. Stock News

Positive

Investors Business Daily

●

3 days ago

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Neutral

Business Wire

●

10 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (“RSUs”) to seventeen new employees under Acadia's 2024 Inducement P...

Neutral

Business Wire

●

18 days ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts dur...

More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office	United States
CEO	Catherine Adams
Employees	654
Founded	1993
Website	acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now